BASO II: a randomised trial for the management of small well-differentiated and special type carcinomas of the breast

Not Applicable

Completed

• Conditions: Breast cancer; Cancer; Breast

• Registration Number: ISRCTN47734678
• Lead Sponsor: Scottish Cancer Therapy Network (UK)

Brief Summary

1. 2007 results in Blamey RW, Chetty U, Bates T. Radiotherapy and/or tamoxifen after conserving surgery for breast cancers of excellent prognosis: BASO II TRIAL. Eur J Cancer Suppl. 2007;5 O-11.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2002-08-19
• Study Completion: 2006-12-31
• Last Update Posted: 3 March 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 0

Inclusion Criteria

1. Aged <70 years
2. Unilateral invasive breast carcinoma grade I or of a special type:
a. Tubular
b. Tubular/cribriform
c. Cribriform
d. Papillary
e. Mucoid
f. Not lobular, medullary or other rarer special types of breast carcinoma
3. Tumour size <2 cm
4. No evidence of vascular invasion
5. The histological examination of at least one lymph node is required. There should be no evidence of metastases
6. No distant metastases
7. No other systemic disease
8. No previous invasive malignant disease, except basal cell carcinoma of the skin adequately treated or adequately treated in situ carcinoma of the cervix

Exclusion Criteria

Patients with bilateral breast cancer, Paget's disease of the nipple, in situ carcinoma only or tumours which are essentially ductal carcinoma in situ but with microinvasion are to be excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified